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ABSTRACT
Induction of necroptosis has emerged as an alternative approach to trigger 
programmed cell death, in particular in apoptosis-resistant cancer cells. Recent 
evidence suggests that kinase inhibitors targeting oncogenic B-RAF can also affect 
Receptor-interacting serine/threonine-protein kinase (RIP)1 and RIP3. Sorafenib, a 
multi-targeting kinase inhibitor with activity against B-RAF, is used for the treatment 
of acute leukemia. In the present study, we therefore investigated whether Sorafenib 
interferes with therapeutic induction of necroptosis in acute leukemia. Here, we report 
that Sorafenib inhibits necroptotic signaling and cell death in two models of necroptosis 
in acute leukemia. Sorafenib significantly reduces Second mitochondria-derived 
activator of caspases (Smac) mimetic-induced necroptosis in apoptosis-resistant 
acute myeloid leukemia (AML) cells as well as Smac mimetic/Tumor Necrosis Factor 
(TNF)α-induced necroptosis in FADD-deficient acute lymphoblastic leukemia (ALL) 
cells. Sub- to low micromolar concentrations of Sorafenib corresponding to its plasma 
levels reported in cancer patients are sufficient to inhibit necroptosis, emphasizing 
the clinical relevance of our findings. Furthermore, Sorafenib blocks Smac mimetic-
mediated phosphorylation of mixed-lineage kinase domain-like protein (MLKL) that 
marks its activation, indicating that Sorafenib targets components upstream of MLKL 
such as RIP1 and RIP3. Intriguingly, Sorafenib reduces the Smac mimetic/TNFα-
stimulated interaction of RIP1 with RIP3 and MLKL, demonstrating that it interferes 
with the assembly of the necrosome complex. Importantly, Sorafenib significantly 
protects primary, patient-derived AML blasts from Smac mimetic-induced necroptosis. 
By demonstrating that Sorafenib limits the anti-leukemic activity of necroptosis-
inducing drugs in acute leukemia cells, our study has important implications for the 
use of Sorafenib in the treatment of acute leukemia.
INTRODUCTION
Necroptosis has recently been identified as a non-
apoptotic form of programmed cell death and the serine/
threonine kinases RIP1 and RIP3 constitute key elements 
of the necroptosis signaling machinery [1]. A prototypic 
signaling pathway to necroptosis is engaged by the 
binding of TNFα to its cognate cell surface receptor TNF 
receptor 1 (TNFR1), which triggers formation of the so-
called complex I at the TNFR1 [1]. This leads to K63-
linked polyubiquitination of RIP1 by cellular Inhibitor 
of Apoptosis (cIAP) proteins and activation of canonical 
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Nuclear Factor kappaB (NF-κB). Upon internalization of 
TNFR1, secondary cell death complexes assemble in the 
cytosol. When caspase-8 activation is blocked, RIP1 is no 
longer cleaved and can interact with RIP3 to build up the 
necrosome resulting in activation of RIP1 and RIP3 in an 
autocrine/paracrine manner via reciprocal phosphorylation 
[2–4]. RIP3 subsequently phosphorylates and activates 
MLKL, a pseudokinase that lacks intrinsic kinase activity 
[5, 6]. Upon its activation, MLKL forms oligomers and 
translocates from the cytosol to the plasma and intracellular 
membranes, where it disrupts membrane integrity [7, 8]. 
Necroptosis may offer an alternative option to 
trigger programmed cell death in cancer cells, as many 
cancers have evolved mechanisms to evade cell death 
[9]. In apoptosis-resistant cancers therapeutic induction 
of necroptosis may be of particular interest, as activated 
caspase-8 has been shown to cleave and thus inactivate 
RIP1 [10]. This implies that apoptosis-resistant cancer 
cells are particularly susceptible to necroptosis.    
Inhibitor of Apoptosis (IAP) proteins are a family of 
proteins that are involved in the regulation of programmed 
cell death [11]. For example, cIAP1 and cIAP2 restrain 
necroptosis by mediating the polyubiquitination of RIP1 
via their E3 ligase activity. Small-molecule inhibitors of 
IAP proteins that resemble Smac, i.e. Smac mimetics, 
stimulate autoubiquitination and proteasomal degradation 
of cIAP proteins, thereby promoting the assembly of the 
necrosome leading to necroptosis under conditions when 
caspase activation is inhibited [9].
The kinase domain of human RIP1 and RIP3 shares 
high sequence similarity with the kinase domain of B-RAF 
[12]. In addition, structural comparison of inhibitor-bound 
RIP1 with the inhibitor-bound oncogenic kinase B-RAF 
revealed partially overlapping binding sites for the RIP1 
inhibitor necrostatin-1 (Nec-1) and the B-RAF inhibitor 
Vemurafenib [12]. This suggests that kinase inhibitors 
that target oncogenic B-RAF might also affect RIP1 and/
or RIP3. Indeed, the B-RAF inhibitor Dabrafenib has 
recently been shown to inhibit RIP3 independently of its 
effect on the B-RAF family members [13]. Sorafenib is 
a multi-targeting tyrosine kinase inhibitor with activity 
against B-RAF, but also against other kinases such as 
FLT3, VEGF, PDGF receptor and c-KIT [14]. It is used 
for the treatment of various malignancies including AML 
and ALL [15, 16]. In the present study, we therefore 
investigated the question as to whether or not Sorafenib 
interferes with necroptosis in apoptosis-resistant acute 
leukemia.
RESULTS
Sorafenib protects AML cells from BV6-induced 
necroptosis
We previously reported that Smac mimetics 
can engage necroptosis in AML cells expressing key 
components of necroptosis signaling when caspase 
activation and apoptosis are blocked [17]. To investigate 
whether Sorafenib modulates necroptosis in AML 
cells, we used the Smac mimetic BV6 in combination 
with the broad-range caspase inhibitor zVAD.fmk to 
trigger necroptotic cell death. Importantly, we found 
that the addition of Sorafenib at subtoxic concentrations 
significantly reduced BV6/zVAD.fmk-induced necroptosis 
in a dose-dependent manner in both Molm-13 and MV4-
11 AML cells (Figure 1A). 
To compare the anti-necroptotic activity of Sorafenib 
to an established RIP3 inhibitor, we used GSK’872, a 
small-molecule inhibitor described to block RIP3 [18]. 
GSK’872 significantly inhibited BV6/zVAD.fmk-induced 
cell death in AML cells (Figure 1B). Since the B-RAF 
inhibitor Dabrafenib has recently been reported to inhibit 
RIP3 by its adenosine-5ʹ-triphosphate (ATP)-competitive 
binding to the enzyme [19], we also tested the effect of 
Dabrafenib on the induction of necroptosis in AML cells. 
Of note, the addition of Dabrafenib significantly reduced 
BV6/zVAD.fmk-stimulated cell death in Molm-13 and 
MV4-11 AML cells (Figure 1C). Comparison of equimolar 
concentrations of Sorafenib, Dabrafenib and GSK’872 in 
AML cells showed that Sorafenib and GSK’872 exhibited 
a comparable potency to reduce necroptotic cell death, 
while Dabrafenib turned out to be the most effective 
inhibitor in this model of necroptosis (Figure 1D).
Since exposure of AML cells to Sorafenib has been 
reported to elicit cell death [20, 21], we monitored cell 
death upon treatment with Sorafenib over an extended 
period of time. Indeed, Sorafenib induced cell death in 
AML cells in a time-dependent manner with a relatively 
slow kinetic and no or little cell death after six to 
24 hours (Figure 1E). Furthermore, we investigated the 
long-term effect of Sorafenib on BV6/zVAD.fmk-induced 
necroptosis. A multi-day assay showed that Sorafenib 
protected both AML cell lines from BV6/zVAD.fmk-
induced necroptosis for up to 24 hours, while it lost its 
protective effects later on, in parallel with becoming 
cytotoxic as single agent (Figure 1E). This shows that the 
inhibitory effect of Sorafenib on necroptosis is not only 
dose- but also time-dependent.
Sorafenib inhibits BV6-induced phosphorylation 
of MLKL in AML cells
Since MLKL is considered as a crucial mediator of 
necroptosis [1], we next investigated whether Sorafenib 
interferes with the phosphorylation of MLKL, which 
marks its activation [1]. Importantly, addition of Sorafenib 
almost completely prevented BV6/zVAD.fmk-stimulated 
phosphorylation of MLKL in both Molm-13 and MV4-11 
AML cells (Figure 2A). Similarly, MLKL phosphorylation 
in response to treatment with BV6/zVAD.fmk was 
suppressed in the presence of GSK’872 or Dabrafenib 
(Figure 2A). This confirms that Sorafenib blocks BV6/
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zVAD.fmk-mediated necroptosis in AML cells and 
indicates that Sorafenib targets components upstream of 
MLKL, such as RIP1 and RIP3.
Smac mimetics act by neutralizing IAP proteins 
and binding of Smac mimetics to cIAP proteins causes 
their ubiquitination and proteasomal degradation [22, 
23]. To confirm that Sorafenib inhibits necroptotic 
signaling rather than interfering with BV6-induced 
depletion of cIAP proteins, we assessed the effects of 
Sorafenib on expression levels of cIAP1 in response to 
BV6 treatment. cIAP2 protein levels were not assessed, 
as cIAP2 is not detectable in Molm-13 and MV4-11 AML 
cells [24]. Neither Sorafenib nor GSK’872 or Dabrafenib 
prevented the BV6-stimulated downregulation of cIAP1 
(Figure 2B).
Sorafenib protects ALL cells from BV6/TNFα-
induced necroptosis
We then extended our experiments to a necroptosis 
model of ALL, since Sorafenib is also used for the 
treatment of ALL [16]. To this end, we used FADD-
deficient Jurkat T-cell ALL cells, which undergo 
necroptosis upon treatment with BV6 in combination with 
TNFα [25, 26]. Importantly, Sorafenib protected FADD-
deficient Jurkat cells significantly at low micromolar 
concentrations from BV6/TNFα-induced necroptosis in 
a dose-dependent manner (Figure 3A). Similarly, BV6/
TNFα-mediated cell death was significantly inhibited 
in the presence of GSK’872 or Dabrafenib (Figure 
3B, 3C). Comparison of equimolar concentrations of 
these inhibitors demonstrated that Sorafenib is slightly 
less potent than GSK’872 to inhibit BV6/TNFα-induced 
necroptotic cell death in FADD-deficient Jurkat cells and 
that Dabrafenib is superior to the latter two inhibitors in 
this setting (Figure 3D). Furthermore, phosphorylation 
of MLKL upon treatment with BV6/TNFα was almost 
completely blocked in the presence of Sorafenib, GSK’872 
or Dabrafenib in FADD-deficient Jurkat cells (Figure 3E). 
Similar to the AML model, neither Sorafenib nor the RIP3 
inhibitors GSK’872 and Dabrafenib interfered with BV6-
imposed depletion of cIAP1 (Figure 3F).
As Sorafenib has been reported to induce cell death 
in ALL cells [27], we monitored the effect of Sorafenib 
over time. Similar to the AML model, the kinetic of 
Sorafenib-triggered cell death was relatively slow with 
no or little cell death after six to 24 hours (Figure 3G). 
At an early time point Sorafenib inhibited BV6/TNFα-
induced necroptosis in FADD-deficient Jurkat cells but 
not anymore after 24 hours of treatment, when it started 
to trigger cell death as single agent (Figure 3G). Together, 
this set of experiments shows that Sorafenib protects ALL 
cells from Smac mimetic/TNFα-induced necroptosis in a 
time-dependent fashion.
Sorafenib inhibits BV6/TNFα-induced assembly 
of the necrosome in acute leukemia cells
As the necrosome complex represents a central 
signaling platform in necroptosis [1], we then asked 
whether Sorafenib alters the formation of the necrosome. 
To address this question, we treated FADD-deficient 
Jurkat cells with BV6/TNFα in the presence and absence 
of Sorafenib, immunoprecipitated RIP1 and analyzed its 
interaction with RIP3. Control experiments confirmed 
that we used equipotent concentrations of Sorafenib, 
Figure 1: Sorafenib protects AML cells from BV6-induced necroptosis. (A–C) Molm13 and MV4-11 cells were treated for 6 
hours (Molm13) or 24 hours (MV4-11) with 3 µM BV6 and 40 µM zVAD.fmk in the presence or absence of indicated concentrations of 
Sorafenib (A), GSK’872 (B) or Dabrafenib (C). (D) Molm13 and MV4-11 cells were treated for 6 hours (Molm13) or 24 hours (MV4-11) 
with 3 µM BV6 and 40 µM zVAD.fmk in the presence or absence of 10 µM Sorafenib, 10 µM GSK’872 or 10 µM Dabrafenib. (E) Molm13 
and MV4-11 cells were treated with or without 3 µM BV6 and 40 µM zVAD.fmk in the presence or absence of 10 µM Sorafenib for the 
indicated time points. (A–E) cell death was determined by PI staining and flow cytometry. Mean and SD of at least three experiments 
performed in triplicate are shown; *P < 0.05; **P < 0.01; ***P < 0.001.
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GSK’872 and Dabrafenib for these immunoprecipitation 
studies that reduced BV6/TNFα-induced cell death to 
a comparable extent by about 50% (data not shown). 
Intriguingly, the presence of Sorafenib reduced the 
BV6/TNFα-stimulated interaction of RIP1 and RIP3 
(Figure 4A). Similarly, Dabrafenib decreased binding 
of RIP3 to RIP1 in response to BV6/TNFα treatment 
(Figure 4A). We also observed that GSK’872 even 
promoted the interaction of RIP1 and RIP3 in BV6/
TNFα-treated cells compared to cells that were 
stimulated with BV6/TNFα in the absence of GSK’872 
(Figure 4A). A possible explanation for this finding is 
that GSK’872 alters the conformation of RIP3 thereby 
unleashing its RHIM-dependent oligomerization with 
RIP1 as recently reported [28]. 
To explore whether the ability of Dabrafenib to 
prevent necrosome assembly correlated with its ability to 
inhibit BV6/TNFα-stimulated necroptosis, we also tested 
a higher concentration of Dabrafenib. Of note, Dabrafenib 
at a concentration of 5 µM, which entirely abrogated 
BV6/TNFα-stimulated cell death (Figure 3C), almost 
completely abolished the interaction of RIP1 and RIP3 in 
response to BV6/TNFα treatment (Figure 4B).
Furthermore, we investigated the question as 
to whether or not Sorafenib regulates the binding of 
MLKL to the necrosome complex. To this end, we 
immunoprecipitated RIP1 and analyzed its interaction 
with MLKL. Interestingly, the presence of Sorafenib 
reduced the BV6/TNFα-stimulated interaction of RIP1 and 
MLKL (Figure 4C). Similarly, the interaction of RIP1 and 
MLKL upon BV6/TNFα treatment was attenuated in the 
presence of GSK’872 or Dabrafenib (Figure 4C). This set 
of experiments demonstrates that Sorafenib interferes with 
the assembly of the necrosome during BV6/TNFα-induced 
necroptosis in leukemia cells.
Sorafenib does not inhibit Smac mimetic-
induced apoptosis in acute leukemia cells
Next, we tested whether Sorafenib specifically 
inhibits BV6-induced necroptosis in acute leukemia cells. 
To this end, we investigated the effect of Sorafenib on 
BV6-induced apoptosis in RIP3-deficient and therefore 
necroptosis-resistant NB4 AML cells as well as in Jurkat 
Figure 2: Sorafenib inhibits BV6-induced phosphorylation of MLKL in AML cells. (A) Molm13 and MV4-11 cells were 
treated for 4½ hours (Molm13) or 11 hours (MV4-11) with 3 µM BV6 and 40 µM zVAD.fmk in the presence or absence of 10 µM 
Sorafenib, 15 µM GSK’872 or 5 µM Dabrafenib. (B) Molm13 and MV4-11 cells were treated for 5½ hours (Molm13) or 7 hours (MV4-11) 
with 3 µM BV6 and 40 µM zVAD.fmk in the presence or absence of 10 µM Sorafenib, 15 µM GSK’872 or 5 µM Dabrafenib. Expression 
levels of MLKL and phospho-MLKL (A) or cIAP1 (B) were assessed by Western blotting, GAPDH served as loading control.
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Figure 3: Sorafenib protects ALL cells from BV6/TNFα-induced necroptosis. (A–C) FADD-deficient Jurkat cells were treated 
for 4 hours with 1 µM BV6 and 1 ng/ml TNFα in the presence or absence of indicated concentrations of Sorafenib (A), GSK’872 (B) or 
Dabrafenib (C). (D) FADD-deficient Jurkat cells were treated for 4 hours with 1 µM BV6 and 1 ng/ml TNFα in the presence or absence of 
10 µM Sorafenib, 10 µM GSK’872 or 10 µM Dabrafenib. (E and F) FADD-deficient Jurkat cells were treated for 2 hours with 1 µM BV6 
and 1 ng/ml TNFα in the presence or absence of 10 µM Sorafenib, 6 µM GSK’872 or 0.6 µM Dabrafenib. Expression levels of MLKL, 
phospho-MLKL and cIAP1 were analyzed by Western blotting, expression of GAPDH served as loading control. (G) FADD-deficient 
Jurkat cells were treated with or without 1 µM BV6 and 1 ng/ml TNFα in the presence or absence of 10 µM Sorafenib for the indicated 
time points. Cell death was determined by FSC/SSC analysis (A–D) or PI staining (G) and flow cytometry. Mean and SD of at least three 
experiments performed in triplicate are shown; *P < 0.05; **P < 0.01; ***P < 0.001.
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wild-type cells, which have previously been shown to 
undergo apoptosis upon BV6/TNFα treatment that is 
blocked by the caspase inhibitor zVAD.fmk [17, 26]. Of 
note, Sorafenib failed to rescue NB4 and Jurkat cells from 
BV6-induced apoptosis (Figure 5A, 5B). 
These findings demonstrate that Sorafenib does not 
protect acute leukemia cells from Smac mimetic-induced 
apoptosis.
Sorafenib rescues primary AML cells from BV6-
induced necroptosis
To investigate the clinical relevance of our results, 
we studied the effects of Sorafenib on necroptosis 
induction in primary leukemic blasts freshly isolated from 
a patient with AML at diagnosis. Importantly, non-toxic 
concentrations of Sorafenib substantially reduced BV6/
zVAD.fmk-induced cell death in primary AML cells 
(Figure 6). This demonstrates that Sorafenib impairs Smac 
mimetic-induced necroptosis not only in AML cell lines 
but also in primary, patient-derived AML blasts.
DISCUSSION
Sorafenib is a multi-targeting tyrosine kinase 
inhibitor that is used for the treatment of e.g. acute 
leukemia [15, 16]. In the present study, we investigated 
whether Sorafenib interferes with therapeutic induction of 
necroptosis in acute leukemia.
Here, we report that Sorafenib inhibits necroptotic 
signaling and cell death in acute leukemia cells, when 
caspase activation and apoptosis are blocked by FADD 
deficiency or zVAD.fmk. This conclusion is supported 
by a number of arguments. First, Sorafenib inhibits 
necroptosis at sub- to low micromolar concentrations with 
a comparable potency to the small-molecule inhibitor 
GSK’872 that has been described to block RIP3 [18]. 
Second, Sorafenib interferes with the assembly of the 
necrosome complex upon the induction of necroptosis 
reducing the interaction of RIP1 with RIP3 and MLKL. 
Third, Sorafenib strongly attenuates phosphorylation of 
MLKL, a posttranslational modification that is mediated 
by RIP3 and marks its activation [5]. This indicates that 
Sorafenib targets components upstream of MLKL such as 
RIP1 and RIP3. 
Sorafenib is a multi-targeting kinase inhibitor that 
inhibits B-RAF in addition to other kinases [14]. The fact 
that it inhibits RIP1 and RIP3 in addition to its known 
targets is supported by recent structural biology studies 
showing a strong structural homology between the kinase 
domains of both human RIP1 and RIP3 and the kinase 
domain of B-RAF [12]. This underscores that kinase 
inhibitors targeting oncogenic B-RAF might also affect 
RIP1 and RIP3. Indeed, there is recent evidence indicating 
that Sorafenib inhibits RIP1 and RIP3 kinase activity [29]. 
Sorafenib has also been reported to induce necroptosis 
based on data showing that the RIP1 inhibitor Nec-1 
attenuated Sorafenib-mediated cell death in multiple 
myeloma, Hodgkin lymphoma or prostate carcinoma cells 
[30–32]. However, as RIP1 can control necroptotic as 
well as apoptotic pathways, Nec-1-conferred protection 
from cell death cannot be taken as sufficient evidence for 
necroptosis.
Besides Sorafenib, other kinase inhibitors that 
are currently being used as anticancer drugs have been 
reported to exhibit anti-necroptotic effects. The B-RAF 
inhibitor Dabrafenib has been shown to inhibit RIP3 
through ATP-competitive binding to the enzyme, to inhibit 
necroptosis in cellular models and to alleviate toxic liver 
injury in vivo [13]. This Dabrafenib-imposed protection 
from necroptosis was described to occur independently 
of its effect on the B-RAF family members [13]. 
Consistently, we show in the present study that Dabrafenib 
protects acute leukemia cells from therapeutic induction 
of necroptosis. Furthermore, a cellular screen with Food 
and Drug Administration (FDA)-approved drugs identified 
the structurally distinct multi-targeting kinase inhibitors 
Pazopanib and Ponatinib as necroptosis inhibitors [33]. 
Ponatinib is a multikinase inhibitor, which targets BCR-
ABL besides other kinases such as VEGF receptor, PDGF 
receptor, FGFR, FLT3 and c-KIT [34] and has been 
developed for the treatment of Philadelphia chromosome-
positive acute leukemia [35]. Ponatinib has been shown 
to inhibit both RIP1 and RIP3 via direct binding [33, 36]. 
The protective effect of Pazopanib, a receptor tyrosine 
kinase inhibitor targeting VEGF receptors, PDGF receptor 
and c-KIT [37], has been reported to be mediated via RIP1 
as the main functional target [33]. Together, these reports 
show that several multi-kinase inhibitors with different 
activity spectra can protect from necroptosis by targeting 
RIP1 and/or RIP3. 
The data on hand showing that Sorafenib can limit 
the anti-leukemic activity of necroptosis-inducing drugs 
in acute leukemia cells has important implications, as 
Sorafenib is currently being used in the clinic for the 
treatment of AML and ALL [15, 16]. The induction of 
necroptosis has emerged in recent years as an alternative 
therapeutic approach to trigger programmed cell death 
in cancer cells, in particular in apoptosis-resistant 
cases [38]. In AML, we recently demonstrated that 
Smac mimetics alone or in combination with standard 
chemotherapeutic drugs such as cytarabine or epigenetic 
modifiers (i.e. demethylating agents, histone deacetylase 
(HDAC) inhibitors) can overcome apoptosis resistance 
of AML cells by inducing necroptosis as an alternative 
mode of programmed cell death [17, 24, 39, 40]. 
Also, Smac mimetics together with glucocorticoids, 
demethylating agents or TNFα have been shown to 
elicit necroptosis in apoptosis-resistant ALL cells [25, 
41, 42]. Our current study demonstrating that Sorafenib 
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Figure 4: Sorafenib inhibits BV6/TNFα-induced assembly of the necrosome in acute leukemia cells. (A) FADD-deficient 
Jurkat cells were treated for 2 hours with 1 µM BV6 and 1 ng/ml TNFα in the presence or absence of 10 µM Sorafenib, 6 µM GSK’872 or 
0.6 µM Dabrafenib. RIP1 was immunoprecipitated using anti-RIP1 antibody and detection of indicated proteins was carried out by Western 
blotting; *: IgG heavy chain. (B) FADD-deficient Jurkat cells were treated for 2 hours with 1 µM BV6 and 1 ng/ml TNFα in the presence or 
absence of 10 µM Sorafenib, 10 µM GSK’872 or 5 µM Dabrafenib. RIP1 was immunoprecipitated using anti-RIP1 antibody and detection 
of indicated proteins was carried out by Western blotting; *: IgG heavy chain. (C) FADD-deficient Jurkat cells were treated for 2 hours 
with 1 µM BV6 and 1 ng/ml TNFα in the presence or absence of 10 µM Sorafenib, 6 µM GSK’872 or 0.6 µM Dabrafenib. RIP1 was 
immunoprecipitated using anti-RIP1 antibody crosslinked to beads and detection of indicated proteins was carried out by Western blotting. 
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at sub- to low micromolar concentrations inhibits 
treatment-induced necroptosis in AML and ALL cells 
implies that Sorafenib may limit the anti-leukemic 
activity of anticancer drugs that trigger necroptosis 
under certain conditions, for example when caspase 
activation is blocked. Nevertheless, additional studies, 
e.g. using in vivo leukemia mouse models, are still 
outstanding to test whether Sorafenib may limit the 
antileukemic activity of necroptosis-inducing agents. 
Also, downregulation of RIP3 has been reported in some 
human cancers including AML [43, 44]. The clinical 
relevance of our findings is underscored by our data 
showing that Sorafenib impairs the therapeutic induction 
of necroptotic cell death by Smac mimetic not only in 
AML and ALL cell lines but also in primary, patient-
derived AML blasts. Furthermore, the concentrations of 
Sorafenib exhibiting anti-necroptotic effects in leukemia 
cells correspond to plasma levels of 3–17 µM Sorafenib 
Figure 5: Sorafenib does not inhibit BV6-induced apoptosis in acute leukemia cells. (A) NB4 cells were treated for 7 hours 
with 7 µM BV6 in the presence or absence of 10 µM Sorafenib. (B) Jurkat cells were treated for 24 hours with 5 µM BV6 and 1 ng/ml 
TNFα in the presence or absence of 5 µM Sorafenib. Cell death was determined by FSC/SSC analysis and flow cytometry. Mean and SD 
of at least three experiments performed in triplicate are shown; *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 6: Sorafenib rescues primary AML cells from BV6-induced necroptosis. Primary AML cells were treated for 36 hours 
with 10 nM BV6 and 20 µM zVAD.fmk in the presence or absence of indicated concentrations of Sorafenib. Cell death was determined by 
PI staining and flow cytometry. Mean and SD of triplicates are shown; *P < 0.05; **P < 0.01; ***P < 0.001.
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that have been reported in cancer patients upon treatment 
with Sorafenib [45, 46]. Taken together, our study has 
important implications for the use of Sorafenib in the 
treatment of acute leukemia.
MATERIALS AND METHODS
Cell culture and chemicals
AML cell lines were obtained from DSMZ 
(Braunschweig, Germany), FADD-deficient Jurkat cells 
were kindly provided by Dr. J. Blenis [47]. Cells were 
cultured in RPMI 1640 medium (Life Technologies, Inc., 
Eggenstein, Germany), supplemented with 10% or 20% 
fetal calf serum (FCS) (Biochrom, Berlin, Germany), 1% 
penicillin/streptomycin (Invitrogen, Karlsruhe, Germany) 
and 1 mM sodium pyruvate (Invitrogen) for AML cell 
lines or 2.5% HEPES (Invitrogen) for ALL cell lines. 
Primary AML cells were maintained in Iscove’s Modified 
Dulbecco’s Medium with GlutaMAX™ supplement 
(Life Technologies) supplemented with 10% FCS, 1% 
penicillin/streptomycin, 1% sodium pyruvate, 1% non-
essential amino acid, 8 ng/ml interleukin-3, 20 ng/ml 
granulocyte-macrophage colony-stimulating factor, 
20 ng/ml stem cell factor and 50 µM 2-mercaptoethanol. 
Biomaterial and clinical data were obtained from the 
hematological biobank and the tumor documentation 
of the UCT Frankfurt (Germany), characteristics of the 
sample are summarized in Supplementary Table 1. The 
study protocol has been approved by the local ethics 
committee of the University Hospital Frankfurt and 
informed consent has been obtained. The Smac mimetic 
BV6, which neutralizes x-linked IAP (XIAP), cIAP1 
and cIAP2 [22], was kindly provided by Genentech, Inc. 
(South San Francisco, CA, USA). Caspase inhibitor zVAD.
fmk was obtained from Bachem (Heidelberg, Germany), 
TNFα from Biomol (Hamburg, Germany), GSK’872 from 
Merck (Darmstadt, Germany), Sorafenib from Bayer AG 
(Leverkusen, Germany), Dabrafenib from Selleckchem 
(Houston, TX, USA). All chemicals were purchased by 
Sigma-Aldrich (Taufkirchen, Germany) or Carl Roth 
(Karlsruhe, Germany) unless indicated otherwise. Cells 
were preincubated with inhibitors (zVAD.fmk, Sorafenib, 
GSK’872 or Dabrafenib) for one hour before treatment. 
BV6 was applied two hours before stimulation with TNFα.
Western blot analysis
Western blot analysis was performed as described 
previously [48] using the following antibodies: cIAP1 
(R&D Systems, Inc., Wiesbaden, Germany), RIP1 
(BD Biosciences, Heidelberg, Germany), RIP3 (Novus 
Biologicals, Littleton, CO, USA), MLKL (GeneTex, 
Irvine, CA, USA), phospho-MLKL (Cell Signaling 
Technologies, Danvers, MA, USA), β-Actin (Sigma-
Aldrich) and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (HyTest, Turku, Finland) as loading controls 
and secondary antibodies conjugated to horseradish 
peroxidase (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA). Enhanced chemiluminescence was used for 
detection (Amersham Bioscience, Freiburg, Germany). 
Alternatively, secondary antibodies labeled with IRDye 
infrared dyes were used for fluorescence detection 
(Odyssey Imaging System, LI-COR Bioscience, Bad 
Homburg, Germany). All Western blots shown are 
representative of at least two independent experiments.
Determination of cell death
Cell death was assessed by forward/side scatter 
(FSC/SSC) analysis and flow cytometry as described 
previously [49] or by determination of plasma membrane 
permeability using propidium iodide (PI) staining (Sigma-
Aldrich) and flow cytometry.
Immunoprecipitation
RIP1 immunoprecipitation was performed as 
previously described [25]. Briefly, cells were lysed in 
nonidet P-40 (NP-40) buffer (10 mM Tris (pH 8.0), 
150 mM NaCl, 1% NP-40), supplemented with protease 
inhibitor cocktail (Roche, Grenzach, Germany) and 
phosphatase inhibitors (1 mM sodium orthovanadate, 
1 mM β-glycerophosphate, 5 mM sodium fluoride). At 
least 1.5 mg of protein was incubated with 1.5 μg of 
mouse anti-RIP1 antibody (no. 610459; BD Biosciences) 
overnight at 4°C followed by the addition of 15 μl pan-
mouse IgG Dynabeads (Invitrogen), and then rotated for 
at least two hours at 4°C and washed with NP-40 buffer. 
Denaturated samples were analyzed by Western blot for 
the expression of RIP1, RIP3 and MLKL. For analyzing 
the interaction of RIP1 and MLKL, the RIP1 antibody was 
crosslinked to beads using dimethyl pimelimidate ((DMP); 
Thermo Scientific, Rockford, USA).
Statistical analysis
Statistical significance was assessed by Student’s 
t-test (two-tailed distribution, two-sample, unequal 
variance). 
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